CLPTM1L and lung carcinoma: In particular, an in vitro study provided evidence that CLPTM1L is oncogenic, specifically for Ras-driven lung cancers, in line with its effect on protecting tumor cells from genotoxic apoptosis [59], and is a promising therapeutic target for therapy-resistant tumors [60].